Rosh Women's Health End of Rotation (EOR) Practice Exam

Rh D immune globulin is typically administered to Rh-negative pregnant women at around 28 weeks of gestation, and again at delivery if the infant is found to be Rh-positive. This protocol is important because it helps prevent hemolytic disease of the newborn in subsequent pregnancies.

The administration at 28 weeks acts as a prophylactic measure, aiming to prevent any potential sensitization that might occur if fetal red blood cells enter the mother's circulation. If the infant is Rh-positive at delivery, the additional dose is crucial to protect future pregnancies. This approach reduces the risk of the mother developing antibodies against Rh-positive blood cells, which can lead to serious complications in future pregnancies.

This regimen is well-established and supported by guidelines to ensure both maternal and fetal health, highlighting the importance of monitoring Rh status throughout pregnancy.